Publikationer COMBAT-MS

2026

• Alping P, Öberg Sysojev A, Piehl F, Frisell T. Eur J Neurol 2026 Jun;33(6):e70656. Alping P, Öberg Sysojev A, Piehl F, Frisell T. Comorbidities for Predicting Progression Independent of Relapse Activity in Multiple Sclerosis Treated With B-Cell Depletion.. Eur J Neurol. 2026;33(6). PMID: 42226439.
   
• Englund S, Reutfors J, Frisell T, Piehl F. Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss. Ann Clin Transl Neurol. 2026;13(4):736–746. PMID: 41262065.
   
• Frisell T, Hedberg S, Piehl F. Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study. Ann Neurol. 2026. Online ahead of print. PMID: 42310849.
   
• Hedström AK, Olsson T, Piehl F, Alfredsson L. Beneficial impact of physical activity on multiple sclerosis disability progression. J Neurol Neurosurg Psychiatry. 2026;97(3):209–216. PMID: 40987566.
   
• Pedersen A, Sandesjö F, Alping P, Frisell T, Piehl F, Fink K, McKay KA. Temporal Trends in the Incidence and Prevalence of Multiple Sclerosis in Sweden, 2001–2021. Neuroepidemiology. 2026. Online ahead of print. PMID: 42207760.
   
• Sandesjö F, McKay KA, Fink K, Piehl F, Wickström R. Treatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study. Mult Scler. 2026;32(8):829–838. PMID: 42218618.
   
• Torkildsen Ø, Brustad HK, Høgestøl EA, Alstadhaug KB, Bhan A, Flemmen HØ, Habbestad A, Høglund RAA, LeBlanc M, Lopen P, Lorentzen ÅR, Morsund ÅH, Lossius A, Lundby R, Nygaard GO, Rød BE, Simonsen CS, Steffensen L, Torgauten H, Piehl F, Wergeland S, Myhr KM; OVERLORD-MS Investigators. Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis. N Engl J Med. 2026;395(1):44–53. PMID: 42384870.

2025

• Pedersen A, Trogù F, Armiento M, Fink K, Frisell T, Piehl F. Correlates of patient reported quality of life in a large multiple sclerosis cohort encompassing the COVID-19 pandemic period. Mult Scler Relat Disord. 2025;104:106755. PMID: 40976205.
   
• Sandesjö F, Alping P, Fink K, Wickström R, Piehl F, Frisell T, McKay KA. Validation of the Swedish Multiple Sclerosis registry for pediatric-onset multiple sclerosis. Mult Scler J Exp Transl Clin. 2025;11(1):20552173251314118. PMID: 39931539.
   
• Skattebøl L, Nygaard GO, Leonardsen EH, Kaufmann T, Moridi T, Stawiarz L, Ouellette R, Ineichen BV, Ferreira D, Muehlboeck JS, Beyer MK, Sowa P, Manouchehrinia A, Westman E, Olsson T, Celius EG, Hillert J, Kockum I, Harbo HF, Piehl F, Granberg T, Westlye LT, Høgestøl EA. Brain age in multiple sclerosis: a study with deep learning and traditional machine learning. Brain Commun. 2025;7(3). PMID: 40337466.

2024

• Alping P, Neovius M, Piehl F, Frisell T. Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study. Ann Neurol. 2024: 95(6):1099-1111. PMID: 38529711.
   
• Englund S, Frisell T, Qu Y, Gandhi K, Hultén A; Kierkegaard M, Piehl F, Longinetti E. Trajectories of self-reported fatigue following initiation of multiple sclerosis disease modulating therapy. J Neurol Neurosurg Psychiatry. 2024: ;95(11):1012-1020. PMID: 38744460.
   
• Hu Y, Frisell T, Alping P, Song H, Pawitan Y, Fang F*, Piehl F*. Hospital-treated infections and risk of disability worsening in multiple sclerosis. Ann Neurol. 2024. Online ahead of print. PMID: 38984615.*Delat seniorförfattarskap.
   
• Longinetti E, Englund S, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould AM, Lycke J, Nilsson P, Salzer J, Svenningsson A, Mellergård J, Olsson T, Piehl F, Frisell T. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy. J Neurol Neurosurg Psychiatry. 2024: 95(2):134-141. PMID: 37558400

2023

• Langer-Gould AM, Smith JB, Gonzales EG, Piehl F, Li BH. Multiple Sclerosis, Disease-Modifying Therapies, and Infections. Neurol Neuroimmunol Neuroinflamm. 2023;10(6):e200164. PMID: 37813594
• Fink K, Gorczyca A, Alping P, Englund S, Farmand S, Langer-Gould AM, Piehl F, McKay K, Frisell T, Razaz N. Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study. Mult Scler. 2023;29(6):731-740. PMID: 37073483
• Englund S, Kierkegaard M, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Mellergård J, Olsson T, Longinetti E, Frisell T, Piehl F. Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort. Mult Scler Relat Disord. 2023: 70:104481. PMID: 36603296

2022

• Starvaggi Cucuzza, C, Longinetti E, Ruffin N, Evertsson B, Kockum I, Jagodic M, Al Nimer F, Frisell T, Piehl F. Sustained low relapse rate with highly variable B cell re-population dynamics with extended rituximab dosing intervals in multiple sclerosis. Neurology Neuroimmunology & Neuroinflammation. 2022; 10(1):e200056. PMID: 36411076
• Longinetti E, Bower H, McKay KA, et al. COVID 19 clinical outcomes and DMT of MS patients and population-based controls. Ann Clin Transl Neurol. 2022;9(9):1449-1458. PMID: 35993445.
• Platten M, Ouellette R, Herranz E, et al. Cortical and white matter lesion topology influences focal corpus callosum atrophy in multiple sclerosis. J Neuroimaging. 2022;1-9. PMID: 35165979.
• Brusini I, Platten M, Ouellette R, Piehl F, Wang C, Granberg T. Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis. J Neuroimaging. 2022;32(3):459-470. PMID: 35083815.

2021

• Alping P, Burman J, Lycke J, Frisell T, Piehl F. Safety of alemtuzumab and autologous hematopoietic stem cell transplantation compared to noninduction therapies for multiple sclerosis. Neurology. 2021;96(11):e1574-e1584. PMID: 33514645.
• Longinetti E, Frisell T, Englund S, Reutfors J, Fang F, Piehl F. Risk of depression in multiple sclerosis across disease-modifying therapies. Mult Scler. 2021;15:13524585211031128. PMID: 34264143.
• Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol. 2021;78(10):1197-1204. PMID: 34398221.
• Platten M, Brusini I, Andersson O, et al. Deep learning corpus callosum segmentation as a neurodegenerative marker in multiple sclerosis. J Neuroimaging. 2021;31:493-500. PMID: 33587820.
• Asplund Högelin K, Ruffin N, Pin E, et al. Development of humoral and cellular immunological memory against SARS-CoV-2 despite B-cell depleting treatment in multiple sclerosis. iScience. 2021;4(9):103078. PMID: 34490414.
• Langer-Gould A, Smith JB, Li BH, et al. Multiple sclerosis, rituximab, and COVID 19. Ann Clin Transl Neurol. 2021;8(4):938-943. PMID: 33783140.
• McKay KA, Piehl F, Englund S, et al. Rituximab infusion timing, cumulative dose, and hospitalization for COVID 19: evidence from the nationwide COMBAT-MS Cohort. JAMA Netw Open. 2021;4(12):e2136697. PMID: 34851401.

2020

• Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184-191. PMID: 31589278.
• Alping P, Askling J, Burman J, et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol. 2020;87(5):688-699. PMID: 32056253.
• Smith JB, Hellwig K, Fink K, Lyell DJ, Piehl F, Langer-Gould A. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e734. PMID: 32358226.
• Razaz N, Piehl F, Frisell T, Langer-Gould AM, McKay KA, Fink K. Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurol Neuroimmunol Neuroinflamm. 2020;7(6):e903. PMID: 33087582. 
• Ouellette R, Treaba CA, Granberg T, et al. 7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis. Brain. 2020;143(10);2973-2987. PMID: 32935834.
• Ouellette R, Mangeat G, Polyak I, et al. Validation of rapid magnetic resonance myelin imaging in multiple sclerosis. Ann Neurol. 2020;87(5):710-724. PMID: 32057118.
• Platten M, Martola J, Fink K, Ouellette R, Piehl F, Granberg T. MRI-based manual versus automated corpus callosum volumetric measurements in multiple sclerosis. J Neuroimaging. 2020;30:198-204. PMID: 31750599.

2019

• Alping P, Piehl F, Langer-Gould A, Frisell T; COMBAT-MS Study Group. Validation of the Swedish Multiple Sclerosis Register: further improving a resource for pharmacoepidemiologic evaluations. Epidemiology. 2019;30(2):230-233. PMID: 30721167.

2018

• Dunn N, Juto A, Ryner M, et al. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler. 2018;24(9):1224-1233. PMID: 28762877.